Immucell 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- ImmuCell reported 3rd quarter 2026 product sales of approximately $8 million, up 46% from the 3rd quarter of 2025; domestic sales rose 29.2% to $6.9 million and international sales rose 573% to $1.1 million.
- Product sales for the first 9 months of 2026 were $25.6 million, up 27.8% year over year; TriShield grew 32.1%, while distributor volumes increased 23% for the period and 18% in the 3rd quarter.
- Gross margin was 44.2% in the 3rd quarter of 2026, compared with 42.9% in the 3rd quarter of 2025 and 33.9% in the 2nd quarter of 2026; higher pricing and improved manufacturing execution contributed to the year-over-year increase.
- Approximately $400,000 of Retain-related expenses shifted to cost of goods sold, reducing stated 3rd quarter gross margin by 480 basis points.
- Sales, marketing, and administrative expenses were $2.4 million versus $1.6 million in the prior-year quarter; product development expenses declined to approximately $175,000 from approximately $700,000.
- Net income was approximately $1 million in the 3rd quarter of 2026, compared with a $140,000 loss in the 3rd quarter of 2025; first 9 months net income was $4.7 million versus $1.8 million.
- Adjusted EBITDA was $1.9 million in the 3rd quarter of 2026 versus $800,000 in the prior-year quarter, and $7.3 million for the first 9 months versus $4.4 million.
- The first 9 months of 2026 included a one-time $2 million legal settlement; the comparable 2025 period included a $427,000 insurance settlement.
- At September 30th, 2026, ImmuCell had $7.9 million of cash, $9.9 million of inventory, approximately $3 million of finished goods inventory, and $16.9 million of working capital.
- Management said new customers contributed about 46% of 3rd quarter net growth and increased utilization by existing customers contributed 54%; dairy customers largely drove 3rd quarter demand.
- Functional Feed had met its full-year targets, and management reported 50% lower pre-weaning removal rates at customer sites using the product.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, and welcome to the ImmuCell Corporation conference call to discuss unaudited third quarter 2026 financial results. All participants will be in a listen-only mode. After today's presentation, there will be an opportunity to ask questions. Please note, this event is being recorded. I would now like to turn the conference over to Joe Diaz of Lytham Partners.
Please go ahead. Thank you, operator.
Good morning, and welcome. As the operator indicated, my name is Joe Diaz with Lytham Partners. We are the investor relations consulting firm for ImmuCell. I thank all of you for joining us today to discuss the unaudited earnings for the third quarter and nine months ended September 30, 2026. Listeners are reminded and cautioned that statements made by management during the course of this call include forward-looking statements, which include any statement that refers to future events or expected future results or predictions about steps the company plans to take in the future. These statements are not guarantees of performance and are subject to risks and uncertainties that could cause actual results, outcomes, or events to differ materially from those discussed today.
Additional information regarding forward-looking statements and the risks and uncertainties that could impact future results, outcomes, or events is available under the cautionary note regarding forward-looking statements provided with the press release that the company filed last night, along with the company's other periodic filings with the SEC. Information discussed on today's call speaks only as of today, Friday, November 13, 2026. The company undertakes no obligation to update any information discussed on today's call. Please note that references to certain non-GAAP financial measures may be made during today's call. With that said, let me turn the call over to Olivier te Boekhorst, President and CEO of ImmuCell Corporation, for some opening remarks.
Oliver? Thanks, Joe, and good morning, everyone.
It's my pleasure to welcome you today to the discussion of ImmuCell's results for the third quarter of 2026. Our discussion of results will be accompanied by a few key slides that are also part of our updated investor presentation. You can find that on our investor page, immucell.com/investors. I will start off today's call with a quick summary of ImmuCell's strategy, which we have developed and refined over the past year. We made the decision in December of 2025 to focus exclusively on First Defense, our bovine scours preventative product line, to take advantage of attractive market tailwinds. High calf values drive producer interest in effective preventatives, and we saw significant opportunity for growth in the U.S. and future international markets.
We stopped investing in a new product for subclinical mastitis called Re-Tain, also driven by our contract manufacturer's inability to obtain GMP approval from the FDA. Our mission became to ensure we had sufficient supply to meet demand for First Defense and to restore our customers' confidence in that ability to supply after a protracted period of supply challenges leading to back orders. We invested in leadership, in expanding our commercial team, in colostrum sourcing capabilities, and importantly, in manufacturing. Our first imperative was to increase manufacturing yields to reliably produce more with existing equipment. Then we followed that with a plan to invest $8 million to increase manufacturing capacity by the end of 2027. We are now looking more closely at improving our product costs and investing in longer-term growth strategies such as international expansion and innovation.
The results this quarter, $8 million in revenue representing 46% growth compared to the third quarter of 2025, 44.2% gross margin, and $1 million net income compared to a $140,000 loss in the third quarter of 2025, tell us that our focus on First Defense is working. Our results reflect the benefits of restored product availability, a favorable domestic calf market, increased commercial activity, and significant improvements in how we manage our supply chain from sourcing to processing colostrum. For a company our size, the singular focus on First Defense and managing our supply chain to support increasing customer demand continues to make a lot of sense, and we are excited to report on our progress today. I will now turn the call over to Timothy Fiori, our Chief Financial Officer, for a deeper review of our third quarter financial results.
Tim? Thank you, Olivier. I will start with a short recap of product sales results, which are unchanged from our October 12th press release.
All the numbers I will speak to are approximate and rounded. Product sales for the third quarter of 2026 came in at $8 million, an increase of 46% compared to the third quarter of 2025. The large year-over-year increase in the third quarter sales reflects, in part, the absence of distributor restocking headwinds that had adversely affected the third quarter sales in 2025. Domestic sales for the third quarter grew 29.2% compared to the third quarter of 2025 to $6.9 million, while international sales for the third quarter grew 573% to $1.1 million in the same period. Sales to Canada accounted for the majority of international growth, boosted in large part by clearing of 2025 back orders.
In the first nine months of this year, we achieved $25.6 million in product sales, a 27.8% increase compared to the first nine months of 2025. Tri-Shield, our flagship product that offers the most advanced protection against neonatal diarrhea, had strong 32.1% growth for the first nine months of 2026. We also assess commercial performance by looking at volume growth at the distributor level. In the first nine months of 2026, distributor volumes grew 23% compared to the same period last year, and 18% in the third quarter of 2026 compared to the third quarter of 2025. Gross margin as a percentage of product sales was 44.2% in the third quarter of 2026, compared to 42.9% in the third quarter of 2025 and 33.9% in the second quarter of this year.
The year-over-year increase in the third quarter primarily reflected higher pricing and improved manufacturing execution, partially offset by the shift of expenses formerly associated with Re-Tain into cost of goods sold. That is an important dynamic that I want to explain a bit more. The shift of Re-Tain product development expenses to cost of goods sold due to the decision to repurpose the Re-Tain facility and equipment to First Defense resulted in approximately $400,000 of expenses being shifted to cost of goods sold, which reduces the Q3 stated gross margin by 480 basis points. The improvement sequentially from the second quarter of this year to the third quarter was primarily driven by increased manufacturing output across all departments, lower scrap, and greater benefits from product pricing. We are seeing benefits from our manufacturing yield improvement projects.
Sales, marketing, and administrative expenses increased to $2.4 million in the third quarter of 2026 compared to $1.6 million in the third quarter of 2025. This was driven by investments in leadership and expanded commercial activities, as previously announced and as Olivier te Boekhorst will be discussing shortly. Product development expenses declined from approximately $700,000 in the third quarter of 2025 to approximately $175,000 in the third quarter of 2026, driven by reductions in spending on Re-Tain product development and the previously mentioned shift of former Re-Tain-related expenses to cost of goods sold. At this point in time, we are not planning any significant future spending on Re-Tain. To wrap up our income statement discussion, our net income was approximately $1 million during the third quarter of 2026, compared to a net loss of $140,000 in the third quarter of 2025.
For the first nine months of 2026, net income was $4.7 million compared to $1.8 million during the same period last year. The nine-month 2026 results include the one-time $2 million legal settlement received from our former contract manufacturer during the second quarter, and the nine months of 2025 results were augmented by a $427,000 insurance settlement. As usual, we provided adjusted EBITDA figures in yesterday's earnings release, together with a reconciliation against net income under GAAP. We believe that looking at adjusted EBITDA assists management and investors by looking at our performance across reporting periods on a consistent basis, excluding certain charges from our reported income before income taxes. Adjusted EBITDA was $1.9 million in the third quarter of 2026, compared to $800,000 in the third quarter of 2025.
For the first nine months of 2026, adjusted EBITDA was $7.3 million compared with $4.4 million during the same period last year. The nine-month year-to-date 2026 figure includes the aforementioned $2 million one-time legal settlement, and the nine-month 2025 results were augmented by the aforementioned $427,000 insurance settlement. To wrap up with financials, let me highlight a few key balance sheet items. Our balance sheet as of September 30, 2026, continues to be in a strong position with $7.9 million of cash on hand and $9.9 million of inventory. We have started spending cash on the First Defense manufacturing capacity expansion, and I will speak more to that in a bit. We are very pleased at this time to be headed into what is typically our busy season with a finished goods inventory of around $3 million.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
7 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
